INFO: NATAP - Latest articles about Hepatitis C - including released reports from DDW 2007 and for all of 2007

[Guest guest]

Latest articles about Hepatitis C. CROI: HOMA-IR Is a Strong Predictor of Rapid Virologic Response in HIV/HCV-co-infected Patients Treated with Pegylated Interferon-alpha 2a and Ribavirin (05/29/07) CROI: Glucose Intolerance Associated with Advancing Liver Disease (Fibrosis) (05/29/07) CROI: Non-Invasive Liver Tests Studies Disappoint at CROI in Coinfection Studies (05/29/07) DDW: Patterns of fat distribution and its relationship to liver histology in nonalcoholic fatty liver disease (NAFLD): does fatty liver cause lipodystrophy? - (05/25/07) DDW: Diabetes Therapy Improves Peg/RBV Response - (05/25/07) DDW: Early Pegasys/RBV Therapy is Cost Effective, Improves Survival & Reduces Risk for Cirrhosis - (05/25/07) DDW: Efficacy and Safety of Peginterferon Alfa-2a/Ribavirin in Methadone Maintenance Patients: Randomized Comparison of Direct Observed Therapy and Self-Administration - (05/25/07) DDW: Patterns of fat distribution and its relationship to liver histology in nonalcoholic fatty liver disease (NAFLD) - (05/24/07) DDW: Cost-effectiveness, Survival,

and Prevention of Cirrhosis with Early Treatment of Chronic Hepatitis C with Peginterferon Alfa-2a (40KD) plus Ribavirin before Progression to Advanced Liver Disease - (05/24/07) DDW: HCV Can Be Cured - (05/24/07) DDW: Treatment Duration and Histological Response to Peginterferon Alfa-2a/Ribavirin: 48 weeks improves liver disease in Non-SVRs better than 24 weeks - (05/24/07) DDW: Safety and Tolerability of Peginterferon Alfa-2a Plus Ribavirin in HCV Patients Nontolerant or Nonresponsive to Peginterferon Alfa-2b Plus Ribavirin - (05/23/07) DDW: Celgosivir with

Peginterferon and Ribavirin in Chronic Hepatitis C - (05/23/07) DDW: Pharmacodynamic Analysis of the Antiviral Activity of the Non-Nucleoside Polymerase Inhibitor, HCV-796, in Combination With Pegylated Interferon Alfa-2b in Treatment-Naive Patients With Chronic HCV - (05/23/07) EASL: Safety, Pharmacokinetics and Antiviral effects of Boehringer Ingelheim BILB 1941, a Novel HCV RNA Polymerase, After 5 days Oral treatment in Patients with Chronic Hepatitis C - (05/21/07) EASL: Phase II Proof of Concept Study of celgosivir in combination woth peginterferon alfa-2a and ribavirin in chronic hepatitis C genotype-1 non responder patients - (05/21/07) DDW: HCV-Infected Liver Donors for Liver Transplantation Are Recommended Instead of Uninfected HCV-Donated Livers, from a new study presented at DDW 2007 - (05/22/07) DDW: HCV-796, Polymerase Inhibitor - (05/22/07) DDW: Eltrombopag Maintains Platelet Counts During Myelosuppressive Pegylated Interferon Alpha Treatment of Chronic Hepatitis C Virus Infection - (05/22/07) DDW: Increased SVR rate with 48 weeks' treatment and higher RBV dose in HCV genotype 2/3 patients without a rapid virologic response (RVR) treated with peginterferon alfa-2a (40KD) (PEGASYS) plus RBV

(COPEGUS) - (05/22/07) DDW: Peginterferon Alfa-2a (40KD) Plus Ribavirin for 16 or 24 Wks in Pts With HCV Genotype 2/3 Infection and Advanced Fibrosis/Cirrhosis - (05/22/07) DDW: Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered ''Cured''; Mitch Shiffman says 'you can cure HCV', Eugene Schiff says 'get treated'. - (05/22/07) DDW: 16 vs 24 wks Pegasys/RBV in Cirrhotics & Non-Cirrhotics Genotype 2/3 from ACCELERATE Study - (05/22/07) DDW: Increased SVR Rate with 48 Wks' Treatment and Higher RBV Dose in HCV Genotype 2/3

Pts Without a Rapid Virologic Response (RVR) Treated with Peginterferon Alfa-2a (40KD) (PEGASYS) Plus RBV (COPEGUS) - (05/21/07) DDW: Statin Improved PegIFN/RBV SVR Rate, Improve ALTs in HCV+ - (05/21/07) DDW: InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting - (05/21/07) Hepatitis D virus infection - Not a vanishing disease in Europe! - (05/03/07) HCV Reinfection: is there protective effect following natural HCV clearance? - (05/03/07) EASL: Pegasys vs Peg/ADV for Hepatitis D Virus: Pegasys most effective - (05/03/07) EASL: HCV Antiviral Activity and Resistance Analysis in Chronically Infected Chimpanzees Treated with Merck NS3/4A Protease and NS5B Polymerase Inhibitors - (05/02/07) EASL: Low-Dose PegIFN Maintenance Therapy Successful - (05/02/07) European Union's CHMP Issues Positive Opinion on PEGINTRON and REBETOL® Combination Therapy for Hepatitis C in Patients Coinfected With HIV - (05/01/07) More gay men getting hepatitis C; Increased HCV Infection

Among HIV+ Gay Men - (05/01/07) EASL: Albuferon Once Every 2 or 4 Weeks Interferon Looks Good in Phase 2 Study - (05/01/07) EASL: Inherited Variants of Genes Involved in Insulin Signaling and Lipogenesis Influence The Risk of Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease - (05/01/07) EASL: Insulin Resistance in HBV, HCV & Non-Virus Related Chronic Hepatitis (liver enzymes) - (05/01/07) EASL: Insulin Resistance Inflames The Liver in HCV - (05/01/07) EASL: Insulin Resistance in 424 HCV+ Patients: association with HCV replication and advanced fibrosis - (05/01/07) EASL: Statins May Improve Liver Fibrosis - (05/01/07) EASL: PegIntron + 2 HCV Nucleosides Show Synergy - (04/27/07) New Genetic Diagnostic Tests-Financial Impact - (04/27/07) EASL: R1479 (R1626), a Novel Hepatitis C Polymerase Inhibitor: Lack of Pre-Existing Resistance Mutations Supports the Observed In Vivo High Barrier to Resistance - (04/27/07) EASL: ITMN-191 CONCENTRATIONS ACHIEVED IN THE LIVER OF ANIMALS PROMOTE HCV REPLICON CLEARANCE IN VITRO AND THIS EFFECT IS ENHANCED BY PEG-IFN a-2a (Pegasys) - (04/27/07) EASL: HCV Protease Inhibitor ITMN-191 Resistance - (04/27/07) HCV Protease Inhibitor ITMN-191 + HCV Polymerase Inhibitor R1626 Synergy - (04/27/07) EASL: Lipid steatosis, metabolic variables and body composition in the setting of HIV/HCV coinfection; findings from a large randomised trial (APRICOT) - (04/26/07) EASL: 400,000 IU/mL

Is New Cut-Off for Low vs High Viral Load in HCV - (04/26/07) EASL: Favorable Cross-Resistance Profile of Two Novel Hepatitis C Virus Inhibitors, SCH 503034 (Boceprevir) and HCV-796, and Enhanced Anti-Replicon Activity Mediated by the Combined Use of Both Compounds - (04/26/07) EASL: SCH503034 & NM283 Not Cross-Resistant - (04/26/07) EASL: An open label, comparative, multi-center study of peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin in the treatment of patients with chronic hepatitis C/hepatitis B dual infection versus with mono-infected chronic hepatitis C: An interim report - (04/25/07) EASL: Virological response at 4 and 12 weeks predict high rates of sustained virological response in genotype 1 patients treated with peginterferon alfa-2a (40KD) plus ribavirin - (04/25/07) EASL: 14 Weeks vs 24 Weeks Peg/RBV for Genotypes 2/3 - (04/20/07) EASL: In vitro Resistance Selection to the HCV Nucleoside Polymerase Inhibitor R1479 (R1626) and to the Protease Inhibitor VX-950 - (04/23/07) EASL: SVR Durable (99%) After 5 Years of Followup - (04/23/07) EASL: 48 Weeks & High Ribavirin Dose

May Improve SVR Rates for Genotype 2/3, French study by Bernard Willems - (04/23/07) EASL: In Patients Who Clear HCV RNA At Week 12 (between week 8 and 12): SVR is Higher After 72 Weeks Than After 48 Weeks Treatment: Results of a Randomized Controlled Trial - (04/23/07) EASL: New HCV Drug Target NS4A Antagonists - (04/23/07) EASL: 3 YEARS OF ADEFOVIR AND LAMIVUDINE COMBINATION THERAPY MINIMIZES THE RISK OF GENOTYPIC RESISTANCE TO ADV IN LAM RESISTANT PATIENTS - (04/20/07) EASL: Abbott HCV Polymerase Inhibitor - (04/18/07) EASL: CANNABIS USE AS AN INDEPENDENT PREDICTOR OF SEVERE STEATOSIS DURING CHRONIC HEPATITIS C - (04/19/07) EASL:3-Drug HCV therapy for 12 weeks: VX950+pegIFN+RBV, interim results from phase II PROVE 1 Trial - (04/17/07) EASL: HCV-796 Polymerase Inhibitor Shows 1.5 log Viral Load Reduction - (04/17/07) EASL: GSK625433: A Novel and Highly potent Inhibitor of the HCV NS5B Polymerase - (04/17/07) EASL: Merck HCV Protease & Polymerase Inhibitor Viral Load Reduction &

Resistance in Chimps - (04/17/07) EASL: GSK625433: A Novel and Highly Potent Inhibitor of the HCV NS5B Polymerase - (04/17/07) EASL: Interim Results Presented at EASL from PROVE 1 Clinical Trial of Investigational Drug Telaprevir in Patients with Genotype 1 Hepatitis C - (04/17/07) EASL: New HCV Drug Target NS4A Antagonists - (04/17/07) EASL: NM283 in Treatment-Naives Looks Better - (04/13/07) EASL: NM283, HCV Polymerase Inhibitor in Non-Responders

- (04/13/07) Omega-3 fatty acids alleviate chemically induced acute hepatitis by suppression of cytokines - (04/12/07) EASL: Resistance to New HCV Antivirals - (04/12/07) EASL: Vertex Pharmaceuticals Announces New Data for Investigational HCV Protease Inhibitor Telaprevir to be Presented at 42nd Annual Meeting of the European Association for the Study of the Liver (EASL) - (04/12/07) EASL: New Clinical Study Results Indicate Higher Early Virologic Response with Celgosivir Combination Therapy in HCV Non-Responders - (04/12/07)

New Once Weekly Oral Interferon Belerofon in Phase 1 - (04/09/07) Viral Hepatitis (HCV, HBV) in HIV Infection REVIEW by Margaret Koziel, n s - (04/09/07) 33% HCV/HIV Coinfected in Milan, Italy - (04/09/07) Viral Hepatitis (HCV, HBV) in HIV Infection REVIEW by Margaret Koziel, n s - (04/05/07) Liver Iron Levels NOT Directly Linked to Fibrosis - (04/03/07) UK Parliament adopts written declaration on Hepatitis C -

(03/29/07) Treatment of Chronic Hepatitis C Virus in African Americans With Genotypes 2 and 3 - (03/27/07) Improved Outcomes After SVR, Interferon Therapy - (03/27/07) CROI: In NYC: Liver Fibrosis During Acute HCV Infection of HIV-infected Men (03/21/07) Hepatitis C virus infection is associated with insulin resistance among older adults with or at risk of HIV infection - (03/21/07) U.S. sees sharp decline in hepatitis cases: CDC - (03/21/07) Hepatitis C in Prison & After Release: 40% infected - (03/21/07) Roche Driving PROGRESS in Treatment of Difficult-to-Cure Hepatitis C Patients With New PEGASYS ® (peginterferon alfa-2a (40KD)) and COPEGUS® (ribavirin) Trial - (03/16/07) Procrit/Epogen FDA Safety Warning - (03/12/07) PEGASYS® Gets European Approval for a Shorter Treatment Duration for Some Genotype 1 and 4 Hepatitis C Patients who Show a Rapid Response to Therapy - (03/06/07) Human Genome Sciences Initiates Phase 3 Clinical Trial of Albuferon® With Ribavirin in

Treatment-Naive Patients With Chronic Hepatitis C Genotypes 2 and 3 - (02/29/07) New HCV Drug R7128 Polymerase Inhibitor - (02/29/07) SVR Improved Quality of Life & Sexual Function in Patients with Advanced Fibrosis in HALT-C Study - (02/20/07) Hepatic Steatosis in Hepatitis C: Comparison of Diabetic and Nondiabetic Patients in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial (HALT-C Study) - (02/16/07) Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients - (02/15/07) Non-invasive markers of liver fibrosis: How to use them in clinical practice? - (02/15/07) Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C (HALT-C Study) - (02/12/07) Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients Completing Peginterferon Alfa-2a/Ribavirin Treatment - (01/26/07) Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients - (02/12/07) Short-duration therapy for hepatitis C & RVR: suitable for all? - (02/12/07) Liver Stiffness Measurement Versus Clinicians' Prediction or Both for the Assessment of Liver Fibrosis in Patients with Chronic Hepatitis C - (02/09/07) Are Noninvasive Liver Fibrosis Tests Ready for Use? There are lots of questions. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C - (02/09/07) Medivir: Clinical Phase I Trial with Hepatitis C Virus Protease Inhibitor Initiated - (02/09/07) Gilead and

Achillion Announce Positive Antiviral Activity of NS4A Antagonist in HCV, But Discontinue GS 9132 (ACH-806) Development - (02/09/07) Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients - (02/01/07) Combination Therapy With Telaprevir and Pegylated Interferon Suppresses Both Wild-Type and Resistant Hepatitis C Virus - (02/01/07) Time-Released Interferon Drug: OctoPlus initiates Locteron Phase II clinical study in chronic hepatitis C - (01/30/07) Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype

1 Patients Completing Peginterferon Alfa-2a/Ribavirin Treatment - (01/26/07) Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: A controlled study - (01/26/07) New Hepatitis C Culture System for Study of Virus - (01/24/07) Coley Suspends Development of HCV Toll-Receptor Drug - (01/23/07) Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia - (01/22/07) Diabetes, HCV and Liver Transplanation - (01/22/07) Arrow Therapeutics Selects a 2nd Hepatitis C Clinical Candidate - (01/22/07) Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis - (01/22/07) Noninvasive Markers of Liver Fibrosis - (01/19/07) Negative-Strand Hepatitis C Virus (HCV) RNA in Peripheral Blood Mononuclear Cells from Anti-HCV-Positive/HIV-Infected Women - (01/11/07) Detection of Hepatitis C Virus (HCV) in Serum and Peripheral-Blood Mononuclear Cells

from HCV-Monoinfected and HIV/HCV- Coinfected Persons - (01/11/07) Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C - (01/09/07) Schering and Orasure in pact to develop oral hepatitis C test - (01/09/07) Successful IFN Therapy in IVDUs on Naltraxone - (01/09/07) Enhancing hepatitis C treatment uptake and outcomes for injection drug users EDITORIAL - (01/09/07) Diet (Food groups) and risk of

hepatocellular carcinoma: A multicenter case-control study in Italy - (01/09/07) Phynova Obtains FDA Approval of its IND to Enter Into a Clinical Trial of PYN17 for the Treatment of Chronic Hepatitis C - (01/09/07) http://www.natap.org/